How Ritedose Addresses Drug Shortages
Ritedose helps address drug shortages by using advanced sterile manufacturing and strategic partnerships to keep essential treatments available.
READ MORE
IN THE NEWS
Manufacturing
Ritedose Honored With SCbio’s 2026 Life Sciences Pinnacle Award for Organizational Contribution
South Carolina’s largest sterile CDMO recognized for visionary leadership, innovation, and community impact at SCbio’s annual Life + Science Conference.
READ MORE
South Carolina Life Sciences Momentum: Ritedose Helps Fuel a Fast-Growing Innovation Hub
Ritedose is helping shape a new era of innovation in South Carolina, where life sciences companies are scaling faster than ever before.
READ MORE
Introducing Ritedose— the Largest CDMO Specializing in Blow-Fill-Seal Technology in the US
This overview explores Ritedose, the largest U.S. pharmaceutical CDMO, and how its aseptic Blow-Fill-Seal technology supports large-scale branded and generic drug manufacturing.
READ MORE
How Ritedose Supports a Stable and Reliable Medication Supply
Learn how Ritedose safeguards patients’ access to critical medications with responsive, high-quality pharmaceutical manufacturing.
READ MORE
Ritedose 2025 Year-In-Review
Ritedose’s 2025 Year-In-Review highlights a year of growth, innovation, and purpose-driven impact, advancing patient access through expanded generics, operational excellence, and community investment.
READ MORE
Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution
The Ritedose Corporation (Ritedose) announced that the U.S. Food and Drug Administration (FDA) approved its manufacturing and distribution of Tobramycin Inhalation Solution to treat patients six years and older with infections of Pseudomonas aeruginosa, a common bacterial infection among cystic…
READ MORE
Leading CDMO Enhances cGMP Lab Infrastructure to Strengthen Position
Ritedose is investing $17M to expand its cGMP labs, adding a 10,000 sq. ft. analytical chemistry facility and a 6,000 sq. ft. microbiology expansion to boost drug development and CDMO capabilities.
READ MORE
How Blow-Fill-Seal Technology Ensures Sterile Medication Delivery
Discover how Ritedose leads the industry in delivering safe, scalable, and contamination-free drug products through advanced BFS innovation.
READ MORE
Ritedose Pharmaceuticals Receives FDA Approval for Generic Formoterol Fumarate Inhalation Treatment for Respiratory Illness
COLUMBIA, SC May 1, 2025 — Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), was granted approval by the US Food and Drug Administration (FDA) to manufacture and market generic formoterol fumarate inhalation solution (20 mcg/2 mL), a treatment…
READ MORE
Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre
COLUMBIA, S.C. April 16, 2025 – Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) is adding a seventh Syntegon packaging line to its state-of-the-art manufacturing facility that will double the company’s capacity.
READ MORE
FEATURED NEWS
RECEIVE THE LATEST NEWS
Get a healthy dose of all things Ritedose. Subscribe now for breaking news alerts, updates, previews, and more.